About the Clinical Trial
This is a investigator-initiated mechanistic phase 3, double-blind, randomized, placebo-controlled study to assess the effect and safety of a medication called semaglutide, on kidney function in overweight people with chronic kidney disease.
Participants will be randomized to receive once weekly subcutaneous injection of semaglutide or placebo for 24 weeks, there are 10 hospital visits to receive assessments, including non-invasive kidney and cardiovascular function tests, thorough blood and urine tests and other methods, since these are informative about overall kidney health.
Travel reimbursement is available.
Eligibility Requirements
Older than 18 years of age, willing to sign Informed Consent
Body Mass index ≥ 27 kg/m2
Decreased kidney function: Albuminuria ≥ 30 mg/g and ≤ 3500 mg/g, estimated Glomerular filtration rate≥ 25 ml/min/1.73m2
On a stable dose of high blood pressure drug such as an Angiotensin-converting enzyme inhibitor or Angiotensin receptor blocker, other blood pressure lowering agents or sodium-glucose cotransporter-2 inhibitors for at least 4 weeks before randomization.